APOBEC3A
MOLECULAR TARGETapolipoprotein B mRNA editing enzyme catalytic subunit 3A
APOBEC3A (apolipoprotein B mRNA editing enzyme catalytic subunit 3A) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting APOBEC3A
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Cefotetan | 1.39 | 3 |
| 2 | Dimethylphenylpiperazinium Iodide | 1.39 | 3 |
| 3 | mg624 | 1.39 | 3 |
| 4 | Cefdinir | 1.10 | 2 |
| 5 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 0.69 | 1 |
About APOBEC3A as a Drug Target
APOBEC3A (apolipoprotein B mRNA editing enzyme catalytic subunit 3A) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented APOBEC3A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
APOBEC3A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.